This suggests CCR5 antagonist treatment may be a promising approach to reduce tumor growth in other solid tumors in which CCL5 plays a pro-tumoral role, such as PCa, where Maraviroc was shown to reduce bone metastasis of intracardially injected PCa cells in mice (125). Here, CCR5 is linked to posterior cortical atrophy.